Optum Infusion Services 308, LLC

Optum Infusion Services 308, LLC, a subsidiary of UnitedHealth Group Incorporated, operates as a prime contractor delivering FDA 503A-compliant pharmaceutical compounding and hazardous chemotherapy preparation services exclusively to the Department of Veterans Affairs across multiple Veterans Integrated Service Networks, competing in full-and-open procurements with no set-aside designations.

Optum Infusion Services 308 specializes in aseptic compounding of patient-specific chemotherapy agents, hazardous drug preparation, and oncology medication formulation for VA inpatient and outpatient infusion therapy programs. The company maintains operational sites in Chandler, Arizona (primary hub); Houston, Texas; Jackson, Mississippi; Biloxi, Mississippi; and Pensacola, Florida, with administrative headquarters in Chandler. Work is performed in compliance with FDA 503A standards, USP 797, 795, and 800 requirements for hazardous and non-hazardous pharmaceutical agents, closed-system drug transfer devices, and IV tubing, with next-day delivery capability as a contractual mandate. Representative prime awards include a $8.2 million indefinite-delivery contract with Veterans Integrated Service Network 16 for hazardous pharmaceutical compounding services at Biloxi and Pensacola VA facilities (awarded October 2024, running through September 2029); a $6 million indefinite-delivery contract with VISN 17 for oncology drug compounding at Dallas VA Healthcare System (awarded November 2025, running through October 2030); a $7.6 million indefinite-delivery contract with VISN 10 for hazardous chemotherapy compounding services across Indiana, Ohio, and Michigan (awarded May 2026, base period through April 2027); and a $1.8 million indefinite-delivery contract with VISN 15 for VISN-wide compounded sterile pharmaceutical preparations (awarded September 2026, running through August 2031).

Customer concentration is extremely high and singular: all 25 awards in the source span six Veterans Integrated Service Networks within the Department of Veterans Affairs Veterans Health Administration. VISN 16 dominates both award volume and potential value with eight awards totaling $16.3 million (42% of the portfolio), followed by VISN 2 with eight awards totaling $4 million and VISN 17 with four awards totaling $7.9 million. VISN 10, VISN 15, and VISN 5 complete the customer set. This concentration reflects Optum Infusion Services 308's position as a specialized sole-source or single-award contractor across individual VA medical centers and networks, with most awards explicitly citing the VA's market research finding that the contractor was the only vendor meeting specialized FDA 503A certification and next-day delivery operational requirements.

The vendor holds fourteen indefinite-delivery contracts and eleven task orders or BPA calls issued against those IDIQs. The IDIQs carry contract ceilings ranging from $117 thousand (VISN 2 Toms River chemocompounding) to $8.2 million (VISN 16 hazardous compounding at Biloxi and Pensacola), with cumulative potential value of approximately $38.4 million. All contracts are firm fixed-price, single-award, and non-set-aside. Activity has accelerated sharply: one award in 2021, two in 2024, twelve in 2025, and ten year-to-date in 2026. Obligated dollars total $4.7 million against combined potential value of $38.4 million, reflecting the typical IDIQ profile where task orders are funded incrementally. Three awards face ultimate completion within the next twenty-four months with combined potential value of $839 thousand, creating recompete exposure for the vendor on those VISN-specific contracts.

Optum Infusion Services 308 operates with no subcontract footprint — all 25 awards are prime awards. The company competes only on VA pharmaceutical compounding vehicles and maintains no presence on government-wide vehicles, GSA Schedules, or multi-agency platforms. Its competitive posture is vertical: single-award IDIQ holder at specific VA medical centers and networks, with task orders flowing incrementally against those ceilings rather than open competition for each order. Work is classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 621999 (All Other Miscellaneous Ambulatory Health Care Services), with PSC codes Q517 (Pharmacy Services) and 6505 (Medical and Surgical Supplies and Devices) appearing across awards.